Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | GRN | P28799 | 1/20 | 0.47 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 16/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.42 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.42 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.42 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14037699 | 0.84 | KDM4E (0.37) | KDM4EGRNSORT1MAPK14MAPT | |
| SCHEMBL286900 | 0.82 | KDM4E (0.46) | KDM4EGRNSORT1MAPK14MAPT | |
| SCHEMBL13004476 | 0.82 | GRN (0.46) | KDM4EGRNSORT1MAPK14MAPT | |
| SCHEMBL14214231 | 0.82 | GRN (0.50) | KDM4EGRNSORT1MAPK14MAPT | |
| SCHEMBL9608955 | 0.82 | ALDH1A1 (0.40) | KDM4ELMNA | |
| Hydrochloric Acid SCHEMBL3766097 | 0.82 | GRN (0.46) | KDM4EGRNSORT1MAPK14MAPT | |
| SCHEMBL13186123 | 0.80 | MAPK14 (0.48) | KDM4EGRNSORT1MAPK14MAPT | |
| SCHEMBL15289971 | 0.79 | KDM4E (0.43) | KDM4EGRNSORT1MAPK14MAPT | |
| SCHEMBL12545850 | 0.78 | GRN (0.34) | KDM4EGRNSORT1MAPK14LMNA | |
| SCHEMBL12951482 | 0.78 | GRN (0.37) | KDM4EGRNSORT1MAPTCNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023122140-A1 | PARP1 INHIBITORS | SYNNOVATION THERAPEUTICS, INC. (US) | 2023-06-29 | — | — | WO | disclosed |
| US-9643977-B2 | Necroptosis inhibitors and methods of use therefor | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-05-09 | — | — | US | disclosed |
| EP-2818472-A1 | Imidazo[4,5-c]pyridine and pyrrolo[3,2-c]pyridine compounds as G-protein-coupled receptor kinase 5 (GRK5) modulators | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2014-12-31 | — | — | EP | disclosed |
| US-20120135975-A1 | Substituted Esters as Cannabinoid-1 Receptor Modulators | MERCK & CO., INC. (US) | 2012-05-31 | — | — | US | disclosed |
| US-20110118245-A1 | RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORP. | 2011-05-19 | — | — | US | disclosed |
| WO-2011037795-A1 | COMPOUNDS WHICH SELECTIVELY MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-03-31 | — | — | WO | disclosed |
| US-7618962-B2 | Pyrazolyl substituted xanthines | PGX HEALTH, LLC (US) | 2009-11-17 | — | — | US | disclosed |
| US-7514435-B2 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-04-07 | — | — | US | disclosed |
| US-20080097078-A1 | Antibacterial activity against vancomycin-resistant bacteria | SHIONOGI & CO., LTD. (JP) | 2008-04-24 | — | — | US | disclosed |
| US-20070149534-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-28 | — | — | US | disclosed |
| US-20070066631-A1 | Pyrazolyl substituted xanthines | ADENOSINE THERAPEUTICS, LLC | 2007-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066631-A1 | Pyrazolyl substituted xanthines | ADORA2B, ADORA2A, ADORA3 | KDM4E 3621/4885GRN 3850/4885SORT1 3940/4885 |
| US-20110118245-A1 | RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | KDM4E 2179/4885GRN 4205/4885SORT1 3415/4885 |
| US-20070149534-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | NTRK2, NTRK3, NTRK1 | KDM4E 1765/4885GRN 2459/4885SORT1 1774/4885 |
| US-20120135975-A1 | Substituted Esters as Cannabinoid-1 Receptor Modulators | CNR1, CNR2, FAAH | KDM4E 2066/4885GRN 2286/4885SORT1 2333/4885 |
| US-20080097078-A1 | Antibacterial activity against vancomycin-resistant bacteria | CSGALNACT1, MON2, NR2C2 | KDM4E 4340/4885GRN 3398/4885SORT1 318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.